Current stock page

Financial Data

ARQT Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

ARQTArcutis Biotherapeutics, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 8/10
$28.26+$0.73 (+2.65%)

Latest quote

  • Momentum
    76
  • Value
    65
  • Quality
    76
  • Risk resilience
    46
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$143.92M$129.86M$105.4M$129.5M$99.22M$81.5M$65.85M$71.36M
Gross Profit$131.46M$118.92M$95.61M$117.82M$90.53M$74.01M$57.02M$64.46M
Operating Income$9.44M$16.43M-$9.09M$18.39M$8.53M-$14.61M-$24.53M-$7.63M
Net Income$8.8M$15.01M-$11.3M$17.4M$7.41M-$15.89M-$25.06M-$10.79M
EPS$0.07$0.11-$0.09$0.14$0.06-$0.13-$0.2-$0.09
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$18.9M$12.64M$2.24M$26.19M-$1.75M$324K-$30.38M-$748K
Capital Expenditure-$97K-$158K$0$0$0-$78K-$608K-$5M
Free Cash Flow$18.8M$12.48M$2.24M$26.19M-$1.75M$246K-$30.99M-$5.75M
Net Cash Provided By Operating Activities$18.9M$12.64M$2.24M$26.19M-$1.75M$324K-$30.38M-$748K
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$524.43M$488.54M$460M$432.97M$370.98M$352.43M$344.11M$348.89M
Total Debt$114.62M$114.14M$114.67M$6.27M$113.77M$110.16M$110.8M$110.59M
Cash And Cash Equivalents$33.37M$34.12M$34.76M$42.91M$47.12M$73.05M$53.1M$71.34M
Total Liabilities$280.46M$267.96M$270.36M$243.49M$212.9M$213.46M$201.45M$191.35M
Total Stockholders Equity$243.97M$220.58M$189.65M$189.48M$158.07M$138.97M$142.66M$157.54M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio123.52129.14——————
P/B ratio15.1416.716.4919.3320.9714.0412.659.37
P/S ratio7.28———————
Debt To Equity0.470.520.60.030.720.790.780.7
Free Cash Flow Yield1.62%1.06%0.86%-0.17%-1.15%-3.66%-6.47%-7.95%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio123.52129.14——————
P/B ratio15.1416.716.4919.3320.9714.0412.659.37
P/S ratio7.28———————
Return On Equity12.26%12.93%-1.25%-8.52%-28.04%-67.11%-90.93%-88.89%
Debt To Equity0.470.520.60.030.720.790.780.7

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe121.44x
Pb15.18x
Revenue Growth Yoy45.05%
EPS Growth Yoy20.48%
Gross Margin91.18%
Operating Margin6.91%
ROE14.18%
ROIC9.51%
Debt To Equity0.47
FCF Yield1.67%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$28.26
Volume858,231
RSI (14)48.27
MACD-0.1
MACD signal0.45
MACD histogram-0.55
ADX (14)24.53
SMA (50)$27.54
SMA (200)$25.38
ATR (14)$1.75
Historical volatility (annualized)97.38%
Volume (20-day average)2.6M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score46/100
Beta1.47
Annual volatility56.50%
Max Drawdown-37.50%
Sharpe Ratio0.59
VaR (95%, 1-day)-4.53%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

ARQT Financial Data FAQ

What is Arcutis Biotherapeutics, Inc.'s revenue?

Arcutis Biotherapeutics, Inc.'s revenue is one of the core financial data points for ARQT. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Arcutis Biotherapeutics, Inc.'s revenue growing?

Revenue growth shows whether Arcutis Biotherapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is ARQT's EPS?

ARQT's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Arcutis Biotherapeutics, Inc.'s net income?

Arcutis Biotherapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Arcutis Biotherapeutics, Inc. generate?

Free cash flow shows how much cash Arcutis Biotherapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Arcutis Biotherapeutics, Inc. have?

Cash and debt help frame ARQT's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.